Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Официальное название

Phase II Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy (FOLFIRINOX3 Pancréas)

Обзор

Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.

Подробное описание

Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.

Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses. Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.

Вмешательства

• Препарат FOLFIRINOX treatment
  Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses. Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression

Первичные конечные точки

• Progression-free survival (PFS) [Срок оценки: 6 months]

Вторичные конечные точки (4)

• Overall survival (OS) [Срок оценки: 24 months]
• Acute and late toxicities (adverses events) [Срок оценки: Until 30 days after the end of treatment]
• Quality of life (QoL) [Срок оценки: Until the end of treatment an average of 14 months]
• Quality of life (QoL) [Срок оценки: Until the end of treatment an average of 14 months]

Критерии участия

Критерии включения

• Male or female age > 18 years at time of study entry
• Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)
• Patients with pancreatic adenocarcinoma
• Patients with unresectable locally advanced pancreatic cancer or metastatic pancreatic cancer
• Patients with no history of chemotherapy (prior adjuvant or neoadjuvant chemotherapy accepted if the time between the end of chemotherapy and recurrence is greater than 12 months) and no history of curative radiotherapy for metastatic or locally advanced disease. Palliative radiotherapy is accepted.
• Patient eligible for treatment with FOLFIRINOX (5-FU, Irinotecan, Oxaliplatin and folinic acid) including but not limited to: No active heart disease An ECG with a QT/QTc interval ˂ to 450 ms for men and ˂ to 470 ms for women. No uncontrolled hypertension defined by systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management. A negative pregnancy test if applicable
• Tumor evaluation (CT scan) performed within 4 weeks (28 days) prior to inclusion with at least one measurable lesion according to RECIST 1.1 criteria
• Patient fit and able to comply with the protocol for the duration of the study, including treatment, visits, scheduled examinations and follow-up.
• Biological, hepatic, renal and serological data within the following limits (tests performed within 7 days of inclusion except for serologies performed within 28 days)
• Information given and informed consent signed
• Patient affiliated to a social security scheme
• Men and women must have an effective contraceptive method.

Критерии исключения

• Patient with neuroendocrine carcinoma or acinar cell carcinoma
• Other cancer in the 5 years preceding inclusion or concomitant (except cancer in situ of the uterine cervix or cutaneous basal cell carcinoma).
• Presence of brain metastasis(es)
• Estimated prognosis < 3 months
• History of grade 4 toxicity to oxaliplatin, irinotecan or 5FU if history of adjuvant/neoadjuvant chemotherapy
• Sequellar toxicity > grade 1 if previous adjuvant/neoadjuvant chemotherapy
• Hypersensitivity to any component of FOLFIRINOX® treatment.
• Current participation or participation within 30 days prior to inclusion in another therapeutic trial with an investigational compound and/or completion of radiotherapy within 10 days prior to the start of treatment
• Evidence of a homozygous or heterozygous DPYD mutation and/or uracilemia >16ng/mL and/or homozygous UGT1A1 genotype.
• Pregnancy, breastfeeding
• Inability to sign informed consent or to undergo medical monitoring of the trial for geographical, social or psychological reasons including, but not limited to, psychiatric illness compromising comprehension of information or conduct of the study.
• Patient under guardianship, curatorship or safeguard of justice.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Франция · 1 центр

• Centre Georges-François Leclerc — Dijon

Идентификаторы

NCT: NCT05988814 · 2023-505889-29-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗